Laleh Majlessi

List of Publications by Year
in descending order

26 papers	2,751 citations	331538 21 h-index	526166 27 g-index
32 all docs	32 docs citations	32 times ranked	2885 citing authors

#	Article	IF	Citations
1	An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. Molecular Therapy, 2022, 30, 2984-2997.	3.7	17
2	Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host and Microbe, 2021, 29, 236-249.e6.	5.1	107
3	Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. Communications Biology, 2021, 4, 713.	2.0	17
4	Brain crossâ€protection against SARSâ€CoVâ€2 variants by a lentiviral vaccine in new transgenic mice. EMBO Molecular Medicine, 2021, 13, e14459.	3.3	25
5	Use of lentiviral vectors in vaccination. Expert Review of Vaccines, 2021, 20, 1571-1586.	2.0	16
6	Intrinsic Antibacterial Activity of Nanoparticles Made of Î²-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. ACS Nano, 2019, 13, 3992-4007.	7.3	42
7	Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections. Particle and Particle Systems Characterization, 2019, 36, 1800360.	1.2	24
8	Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors. Cell Reports, 2018, 23, 1072-1084.	2.9	28
9	Unexpected Genomic and Phenotypic Diversity of Mycobacterium africanum Lineage 5 Affects Drug Resistance, Protein Secretion, and Immunogenicity. Genome Biology and Evolution, 2018, 10, 1858-1874.	1.1	47
10	RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection. PLoS Pathogens, 2018, 14, e1007139.	2.1	36
11	Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection. Cell Reports, 2017, 18, 2752-2765.	2.9	98
12	Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. Scientific Reports, 2017, 7, 5390.	1.6	74
13	CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection. PLoS Pathogens, 2016, 12, e1005770.	2.1	50
14	Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access. Cellular Microbiology, 2016, 18, 1070-1077.	1.1	26
15	ESX secretion systems: mycobacterial evolution to counter host immunity. Nature Reviews Microbiology, 2016, 14, 677-691.	13.6	306
16	Release of mycobacterial antigens. Immunological Reviews, 2015, 264, 25-45.	2.8	77
17	Ecto-5â€²-Nucleotidase (CD73) Deficiency in Mycobacterium tuberculosis-Infected Mice Enhances Neutrophil Recruitment. Infection and Immunity, 2015, 83, 3666-3674.	1.0	14
18	Strong Immunogenicity and Cross-Reactivity of Mycobacterium tuberculosis ESX-5 Type VII Secretion -Encoded PE-PPE Proteins Predicts Vaccine Potential. Cell Host and Microbe, 2012, 11, 352-363.	5.1	102

#	Article	IF	Citations
19	Disruption of the ESXâ€5 system of <i>Mycobacterium tuberculosis</i> causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. Molecular Microbiology, 2012, 83, 1195-1209.	1.2	178
20	Control of M. tuberculosis ESAT-6 Secretion and Specific T Cell Recognition by PhoP. PLoS Pathogens, 2008, 4, e33.	2.1	234
21	An Increase in Antimycobacterial Th1-Cell Responses by Prime-Boost Protocols of Immunization Does Not Enhance Protection against Tuberculosis. Infection and Immunity, 2006, 74, 2128-2137.	1.0	93
22	High Frequency of CD4+ T Cells Specific for the TB10.4 Protein Correlates with Protection against Mycobacterium tuberculosis Infection. Infection and Immunity, 2006, 74, 3396-3407.	1.0	86
23	Dissection of ESAT-6 System 1 of Mycobacterium tuberculosis and Impact on Immunogenicity and Virulence. Infection and Immunity, 2006, 74, 88-98.	1.0	279
24	Functional Analysis of Early Secreted Antigenic Target-6, the Dominant T-cell Antigen of Mycobacterium tuberculosis, Reveals Key Residues Involved in Secretion, Complex Formation, Virulence, and Immunogenicity. Journal of Biological Chemistry, 2005, 280, 33953-33959.	1.6	133
25	Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nature Medicine, 2003, 9, 533-539.	15.2	571
26	CD8 + -T-CellResponses of Mycobacterium-Infected Mice to a Newly Identified MajorHistocompatibility Complex Class I-Restricted Epitope Shared byProteins of the ESAT-6Family. Infection and Immunity, 2003, 71, 7173-7177.	1.0	52